Tools
Author: Radia T. Jamil Author: Lisa A. Foris Editor: Jessica Snowden
Updated: 6/12/2023 8:18:02 PM
Introduction
Proteus mirabilis, part of the Enterobacteriaceae family of bacilli, is a gram-negative, facultative anaerobe with an abilityto ferment maltose and inabilityto ferment lactose.P. mirabilis also has swarming motility and the ability to self-elongate and secrete a polysaccharide when in contact with solid surfaces; this allows for attachment and easy motility along surfaces (e.g., medical equipment). The flagella of P. mirabilis are what allow for its motility; not only does this help support colonization, but it also has been associated with its ability to form biofilms and is suggested to contribute to resistance to host defenses and certain antibiotics.[1][2][3][4]
Proteus is found abundantly in soil and water, and although it is part of the normal human intestinal flora (along with Klebsiella species, and Escherichia coli), it has been known to cause serious infections in humans.
Etiology
Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Already have an account? Log in
Etiology
Ninety percent of Proteus infections occur as a result of P. mirabilis, and these are considered community-acquired infections. [4][5][6]
Though not a common cause of nosocomial infections, Proteus species have also been shown to cause infection from the colonized skin and oral mucosa of patients and personnel working in a hospital or long-term care facility.
Patients who acquire an infection in the hospital, have a history of recurrent infections, structural abnormalities of the urinary tract, or urethral instrumentation have a greater risk of acquiring an infection by Proteus (in addition to other organisms such as Klebsiella, Enterobacter, Pseudomonas, Staphylococci, and Enterococci).
Urinary tract infections (UTIs) occur as a result of bacterial migration along the mucosal sheath of the catheter or up the catheter lumen from contaminated urine.[7][8]
Epidemiology
The most common clinical manifestations of Proteus infection are urinary tract infections (UTIs). In general, UTIs are more common in individuals aged 20 to 50 years and most common in women of this age group. In otherwise healthy women, Proteus accounts for 1% to 2% of all UTIs (E.coli being the most common), while in hospital-acquired UTIs, Proteus accounts for 5%. Complicated UTIs (i.e., secondary to catheterization) have an even higher association with Proteus infection at 20% to 45%.
Risk factors for UTIs include sexual activity in both men and women, unprotected anal intercourse in men, an uncircumcised penis, or immunodeficiency (e.g., CD4 count less than 200/uL).
Other factors that may increase the risk of infection by P. mirabilis include female sex, longer duration of catheterization, improper catheter cleaning or care, underlying illness, and lack of availability of systemic antibiotics.
In the United States, gram-negative bacteremia occurs as a result of genitourinary tract infections in 35% of patients.
Pathophysiology
The interaction between P. mirabilis and the host defense (immune) system determines the resultant infection. Proteus species have an extracytoplasmic outer membrane, like other gram-negative bacteria, which contains lipoproteins, polysaccharides, lipopolysaccharides, and a lipid bilayer. Different components of this membrane interact with the host and host defense mechanisms to determine the organism’s virulence. Additionally, the size of the inoculum has a positive correlation with the level of infection.
Attachment of P. mirabilis to host tissue depends on the activity of its fimbriae (or pili), which aretiny projections on the bacterium surface. The tips of these fimbriae also contain certain compounds and polysaccharides that allow for attachment to specific sites in the host organism (e.g., endothelium of the urinary tract) or other inanimate surfaces (e.g., medical devices).
Once Proteus species attach to the target site, a cascade of events is initiated in the host cell, including interleukin (IL) 6 and IL-8 secretion in addition to apoptosis and epithelial cell desquamation.Proteus species also produce urease, which has been shown to be associated with an increased risk of pyelonephritis and upper UTIs.Proteus species also hydrolyze urea to ammonia, thereby alkalinizing the urine. Through the production of urease and ammonia, Proteus can produce an environment where it can survive. Additionally, alkaline urine will decrease the solubility of both organic and inorganic compounds, encouraging precipitation and struvite (e.g., magnesium ammonium phosphate and calcium carbonate-apatite) stone formation.
Like other gram-negative bacteria, Proteus species release endotoxin (part of the gram-negative bacterial cell wall) when invading the bloodstream; thereby triggering additional host inflammatory responses which can ultimately result in sepsis or systemic inflammatory response syndrome (SIRS), a severe condition with a 20% to 50% associated incidence of mortality.
History and Physical
Individuals with a Proteus infection may present with urethritis, cystitis, prostatitis, or pyelonephritis. A history of frequent renal stones may be indicative of an underlying chronic Proteus infection.
Urethritis typically presents with dysuria, pyuria (with or without urethral discharge), and increased urinary frequency. Symptoms are often mild and frequently ignored by patients.
Cystitis, on the other hand, tends to present acutely with dysuria, increased frequency, and urgency of urination, suprapubic or back pain, small volume urine, dark urine, or hematuria. Patientsalsomay present with a fever which may be indicative of a more severe condition, such as pyelonephritis, bacteremia, or impending sepsis.
Prostatitis occurs more acutely in men than cystitis, with the same set of symptoms, though may also be accompanied by fever and chills. Prostatitis tends to be more common with increased age. If there is an associated obstruction, patientsalsomay complain of perianal pain. A diffusely swollen and tender prostate may be noted on palpation during a physical examination.
Pyelonephritis occurs as a complication of either of the conditions mentioned above, and the patient may, therefore, complain of symptoms of urethritis or cystitis. Additional symptoms that are more definitive of pyelonephritis include flank pain, costovertebral angle tenderness, nausea and vomiting, fever, hematuria, and occasionally an enlarged kidney felt on palpation.
Evaluation
The most definitive form of evaluation for an acute P. mirabilis infection is a culture.Proteus species are gram-negative, rod-shaped, and facultatively anaerobic. The majority of strains are lactose negative with characteristic swarming motility that will become evident on agar plates. One must always correlate positive culture results with the clinical presentation of the patient to form anaccurate diagnosis.
Additional evaluations include urine sample analysis to evaluate for pyuria and leukocyte esterase. Pyuria is generally present in the case of bacterial urinary tract infection, such that lack of pyuria may indicate an alternate cause of symptoms. Leukocyte esterase dipstick provides a good alternative to microscopy but is a less sensitive test than microscopic examination. Gram staining of urine may help reveal microscopic bacteriuria which would confirm infection,although the absence of bacteriuria does not exclude it.
A patient with a history of chronically alkaline urine in combination with a positive Proteus culture should be evaluated for renal stones (struvite stones).
If resolution is not seen with antibiotic therapy alone, an ultrasound of the kidneys or a CT abdomen may be warranted to rule out renal stones or a perinephric abscess.
Treatment / Management
Empirical treatment for an uncomplicated UTI caused by P. mirabilis (much like other uncomplicated UTIs) involves outpatient treatment with either a 3-day course of trimethoprim/sulfamethoxazole (TMP/SMZ) or an oral fluoroquinolone (e.g., ciprofloxacin).[9][10][11](A1)
Acute, uncomplicated pyelonephritis can be treated on an outpatient basis with fluoroquinolones, although a regimen of 7 to 14 days is recommended. An alternative to this treatment is a one-time dose of ceftriaxone or gentamycin followed by either TMP/SMZ, an oral fluoroquinolone, or cephalosporin for 7 to 14 days.
If a patient has a more severe condition or is in an inpatient setting, they may begin antibiotic therapy via intravenous administration of either ceftriaxone, gentamycin, fluoroquinolone, gentamycin plus ampicillin, or aztreonam until fever resolves. At this point, they may switch to oral therapy with either cephalosporin, an oral fluoroquinolone, or TMP/SMZ for up to 14 additional days.
If a patient presents with a complicated UTI (e.g., a man or woman with a history of an underlying condition that may increase the risk of failure of therapy), they may also be treated in an outpatient setting with oral antibiotics for 10 to 21 days as long as they receive adequate follow-up.
Proteus infection can be avoided with proper sanitation and hygiene, such as adequate sterilization of medical equipment and surfaces. Additionally, catheterization should be reserved for patients for whom there is no other option.
Differential Diagnosis
Other Gram-negative bacteria, such as E. coli or Klebsiella species, may cause similar clinical presentations with UTI and/or bacteremia. Bacterial culture is essential to identify the causative organism of infection and target therapy appropriately.
Prognosis
The vast majority of proteus infections are associated with the urinary tract. Most of the infections are sensitive to the currently available antibiotics and the outcomes are good in immunocompetent patients.
Complications
Symptoms generally resolve without complications in immunocompetent patients. Immunocompromised patients can be at higher risk for sepsis or prolonged infections.
Deterrence and Patient Education
Decreasing risk factors such as prolonged catheterization can decrease the risk of infection.
Enhancing Healthcare Team Outcomes
Proteus infections are best managed by an interprofessional team that includes physicians, nurses, and pharmacists. Infectious disease specialists may also be helpful, particularly in cases of resistant infections, device-associated infections, or immunocompromised patients.
References
[1]
Marcon J, Schubert S, Stief CG, Magistro G. In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections. Infection. 2019 Dec:47(6):937-944. doi: 10.1007/s15010-019-01315-4. Epub 2019 May 8 [PubMed PMID: 31069724]
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[2]
Majeed HT, Aljanaby AAJ. Antibiotic Susceptibility Patterns and Prevalence of Some Extended Spectrum Beta-Lactamases Genes in Gram-Negative Bacteria Isolated from Patients Infected with Urinary Tract Infections in Al-Najaf City, Iraq. Avicenna journal of medical biotechnology. 2019 Apr-Jun:11(2):192-201 [PubMed PMID: 31057723]
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[3]
Pavez M, Troncoso C, Osses I, Salazar R, Illesca V, Reydet P, Rodríguez C, Chahin C, Concha C, Barrientos L. High prevalence of CTX-M-1 group in ESBL-producing enterobacteriaceae infection in intensive care units in southern Chile. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2019 Mar-Apr:23(2):102-110. doi: 10.1016/j.bjid.2019.03.002. Epub 2019 Apr 24 [PubMed PMID: 31028724]
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[4]
Wang S, Zhang Y, Zhang X, Li J. An evaluation of multidrug-resistant (MDR) bacteria in patients with urinary stone disease: data from a high-volume stone management center. World journal of urology. 2020 Feb:38(2):425-432. doi: 10.1007/s00345-019-02772-0. Epub 2019 Apr 25 [PubMed PMID: 31025083]
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[5]
Potron A, Hocquet D, Triponney P, Plésiat P, Bertrand X, Valot B. Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community. Antimicrobial agents and chemotherapy. 2019 Jun:63(6):. doi: 10.1128/AAC.00191-19. Epub 2019 May 24 [PubMed PMID: 30962345]
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[6]
O'Keefe LC, Koelle P, McGee Z, Dewberry LS, Wright C, Stallings JE, Gates E, Chittur K. Innovations in Worksite Diagnosis of Urinary Tract Infections and the Occupational Health Nurse. Workplace health & safety. 2019 Jun:67(6):268-274. doi: 10.1177/2165079919834310. Epub 2019 Mar 29 [PubMed PMID: 30924742]
[7]
Odoki M, Almustapha Aliero A, Tibyangye J, Nyabayo Maniga J, Wampande E, Drago Kato C, Agwu E, Bazira J. Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda. International journal of microbiology. 2019:2019():4246780. doi: 10.1155/2019/4246780. Epub 2019 Feb 17 [PubMed PMID: 30906323]
[8]
Meini S,Tascini C,Cei M,Sozio E,Rossolini GM, AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019 Mar 6; [PubMed PMID: 30840201]
[9]
Pelling H, Nzakizwanayo J, Milo S, Denham EL, MacFarlane WM, Bock LJ, Sutton JM, Jones BV. Bacterial biofilm formation on indwelling urethral catheters. Letters in applied microbiology. 2019 Apr:68(4):277-293. doi: 10.1111/lam.13144. Epub [PubMed PMID: 30811615]
Level 3 (low-level) evidence
[10]
Duarte MJ, Kozin ED, Barshak MB, Reinshagen K, Knoll RM, Abdullah KG, Welling DB, Jung DH. Otogenic brain abscesses: A systematic review. Laryngoscope investigative otolaryngology. 2018 Jun:3(3):198-208. doi: 10.1002/lio2.150. Epub 2018 Apr 25 [PubMed PMID: 30062135]
Level 1 (high-level) evidence
[11]
Armbruster CE, Mobley HLT, Pearson MM. Pathogenesis of Proteus mirabilis Infection. EcoSal Plus. 2018 Feb:8(1):. doi: 10.1128/ecosalplus.ESP-0009-2017. Epub [PubMed PMID: 29424333]